Topic Hub
25 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 25 of 25 clinical reviews.
A physician-reviewed guide to using AndroGel (testosterone 1% and 1.62% gel) in men with autoimmune conditions, covering immune modulation, drug interactions, monitoring protocols, and clinical trial data.
Read clinical reviewA clinician-level review of AndroGel (testosterone gel 1%/1.62%) and kidney outcomes: what the T-Trials, pharmacokinetic data, and current guidelines say about renal protection and renal risk in hypogonadal men.
Read clinical reviewA physician-reviewed guide to how AndroGel (testosterone gel 1% and 1.62%) affects appetite, hunger signaling, and food cravings in men with hypogonadism, with primary-literature citations throughout.
Read clinical reviewA physician-level review of how AndroGel (testosterone gel 1% and 1.62%) affects bone mineral density in hypogonadal men, covering T-Trials data, DXA monitoring intervals, and evidence-based clinical protocols.
Read clinical reviewA physician-reviewed breakdown of AndroGel (testosterone gel) cancer risk signals, covering prostate cancer, cardiovascular-adjacent oncology findings, and the T-Trials data. Includes real doses, trial names, and clinical decision guidance.
Read clinical reviewA clinician-level review of AndroGel (testosterone gel 1% and 1.62%) cardiovascular safety data, including the T-Trials, TRAVERSE, and FDA label updates. Covers MACE risk, hematocrit changes, and monitoring protocols.
Read clinical reviewA clinical review of AndroGel (testosterone gel 1.62%) effects on memory, processing speed, and cognitive function in hypogonadal men, including T-Trials data, dosing, and monitoring guidance.
Read clinical reviewA physician-reviewed comparison of compounded testosterone gel versus branded AndroGel, covering pharmacokinetics, cost, safety, regulatory status, and how to choose between them.
Read clinical reviewA GRADE-graded review of AndroGel (testosterone 1% and 1.62% gel) clinical evidence covering the T-Trials, pharmacokinetics, sexual function, bone density, cardiovascular signals, and current prescribing guidelines for male hypogonadism.
Read clinical reviewA clinician-level review of how AndroGel (testosterone gel 1% and 1.62%) affects scalp hair, body hair, sebum production, acne, and skin thickness, with primary-literature citations and practical management guidance.
Read clinical reviewA clinician-reviewed breakdown of how AndroGel (testosterone gel 1% and 1.62%) affects liver enzymes, hepatic metabolism, and long-term liver safety, with primary-literature citations.
Read clinical reviewA physician-reviewed look at how AndroGel (testosterone gel 1% and 1.62%) affects mood, depression, cognitive function, and mental health in hypogonadal men, with data from the T-Trials and other primary sources.
Read clinical reviewA clinician-level review of how AndroGel (testosterone gel 1% and 1.62%) affects resting metabolic rate, fat oxidation, lean mass, insulin sensitivity, and overall energy expenditure in men with hypogonadism.
Read clinical reviewA clinician-level review of AndroGel (testosterone 1% and 1.62% gel) microdosing protocols, including evidence from the T-Trials, FDA labeling, and practical titration strategies for male hypogonadism.
Read clinical reviewEvidence-based strategies for preserving and building lean mass while using AndroGel (testosterone gel 1% and 1.62%) for male hypogonadism, including dosing, exercise, nutrition, and monitoring protocols.
Read clinical reviewWhy testosterone gel stops working and how clinicians fix it. Complete MD-level guide to AndroGel plateau, non-response, absorption failures, and dose optimization with primary-literature citations.
Read clinical reviewTopical testosterone gel (AndroGel) after bariatric surgery presents unique pharmacokinetic and clinical challenges. Learn how absorption changes, dosing adjustments, and monitoring protocols differ in post-bariatric patients with hypogonadism.
Read clinical reviewComplete clinical guide to the AndroGel (testosterone gel 1%/1.62%) pre-surgery hold window: how long to stop before procedures, why polycythemia and thrombotic risk drive the recommendation, and what labs to check before resuming.
Read clinical reviewStopping AndroGel triggers predictable hormonal rebound effects including suppressed LH, FSH, and endogenous testosterone. Learn what the clinical evidence says, how long recovery takes, and what your doctor can prescribe to speed restoration.
Read clinical reviewWhen and how to safely restart AndroGel (testosterone 1% or 1.62% gel) after acute illness. Covers timing, lab reassessment, dose titration, and current guideline recommendations with primary-literature citations.
Read clinical reviewHow temperature, sweat, humidity, and seasonal vitamin D shifts affect AndroGel (testosterone gel 1% and 1.62%) absorption, dosing, and monitoring. Evidence-based guidance from the T-Trials and current Endocrine Society guidelines.
Read clinical reviewA physician-reviewed deep dive into how AndroGel (testosterone gel 1% and 1.62%) affects libido, erectile function, and sexual activity in hypogonadal men, with primary-trial data, dosing details, and clinical guidance.
Read clinical reviewA physician-reviewed deep dive into how AndroGel (testosterone gel 1% and 1.62%) affects sleep architecture, REM cycles, slow-wave sleep, and sleep-disordered breathing in men with hypogonadism.
Read clinical reviewHow to time AndroGel application across time zones, store testosterone gel safely while traveling, and maintain stable serum testosterone levels during long-haul trips. Reviewed by HealthRX physicians.
Read clinical reviewA week-by-week breakdown of what to expect in your first month on AndroGel (testosterone gel 1% / 1.62%), backed by primary clinical trial data and physician-level dosing guidance.
Read clinical review